The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells
A fantastic article in Endpoint News about the collaboration between PsiOxus and the Parker Institute for Cancer Immunotherapy.
“ALL-IN-ONE VIRUSES” How PsiOxus is building a gene therapy cancer platform on its oncolytic virus – BIOCENTURY
Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells wherever they reside.
Turning tumor cells into drug factories – Nature
An intravenously administered oncolytic virus platform delivers combinations of therapeutic genes specifically to solid tumors to enable a potent anticancer immune response while minimizing systemic toxicity.
Abingdon based PsiOxus a new entrant in the Hiscox Tech Track 100 league table – Sunday Times
The Sunday Times Hiscox Tech Track 100 league table ranks Britain’s 100 private tech (TMT) companies with the fastest-growing sales over their latest three years.
PsiOxus is proud to be listed as part of the Fierce 15 – FierceBiotech
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the best and brightest management teams, and we want to see the promise that they hold in their hands has, in this industry built on the all-or-nothing of risk and reward, a genuine chance of being the Next Big Thing.
When we look at the science, the teams, and talk to their leaders, the key issue is the future: In the next 5 to 10 years, could their product or platform produce something revolutionary and game-changing? Does it have a shot at becoming the new standard of therapy in its respective area?
This year’s crop comprises some of the best-funded startups we’ve seen and speaks volumes about the rude health of early-stage biomedical research.